<DOC>
	<DOC>NCT00648739</DOC>
	<brief_summary>The purpose of this study is to determine the safety and best dose of ALXN6000 in treating relapsing or refractory B-CLL or MM and to study how ALXN6000 may help the immune system fight cancer.</brief_summary>
	<brief_title>Safety and Dose Ranging Study of ALXN6000 to Treat Relapsing or Refractory CLL or MM</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms, Plasma Cell</mesh_term>
	<mesh_term>Leukemia, Lymphoid</mesh_term>
	<mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
	<criteria>Relapsing or Refractory B CLL or MM ECOG performance status 02 Anticipated survival of greater than 6 months. Female patients of childbearing potential must agree to use two forms of contraception Patients must have a standard indication for treatment of their malignancy Is willing and able to give written informed consent. Absolute neutrophil count (ANC) &lt; 1000 x 109/L Platelet count &lt; 50,000 x 109/L Pregnant or lactating women. Prior history of autoimmune hemolysis requiring therapy. Prior history of immune thrombocytopenia. Active autoimmune disease requiring immunosuppressive therapy. Positive Coombs' Test (neither Direct or Indirect) Ongoing corticosteroid treatment equivalent to the mineralocortacoid potency of 10 milligram (mg) /day of prednisone, or greater, for any condition. Prior stem cell transplantation within 4 weeks prior to enrollment. Prior chemotherapy for the applicable malignancy within 30 days of enrollment. Neurosurgery or cranial radiation therapy within one year of enrollment. Clinically significant renal, hepatic or heart disease.</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>B-cell Chronic Lymphocytic Leukemia</keyword>
	<keyword>Leukemia</keyword>
	<keyword>Multiple Myeloma</keyword>
	<keyword>CD200</keyword>
	<keyword>Anti-CD200</keyword>
</DOC>